Editing CSL Limited (section)

=== Plasma fractionation and Wiener directorship ===
In 1952, operation commenced plasma fractionation.<ref>{{Cite book|last1=Flood|first1=Phillip|url=https://www1.health.gov.au/internet/main/publishing.nsf/Content/B3B4E1D741764DD2CA257BF000193A6F/$File/plasma_FINAL%20as%20at%2030%20November%202006.pdf|title=Review of Australia's Plasma Fractionation Arrangements|last2=Wills|first2=Peter|last3=Lawler|first3=Peter|last4=Ryan|first4=Graeme|last5=Rickard|first5=Kevin A.|year=2006|isbn=1-74186-121-7}}</ref> Thereafter the range of antivenoms increased, including those against other snake species such as death adder (''[[Acanthophis antarcticus]]'') and the taipan (''[[Oxyuranus scutellatus]]''), plus spiders including the redback (''[[Latrodectus hasselti]]'') and – after much difficulty – the Sydney funnel-web (''[[Atrax robustus]]''). Much of this work, including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes, occurred under the direction of [[Saul Wiener]], while from 1966 until the mid-1990s, venom research was coordinated by the eccentric but dedicated [[Struan Sutherland]], who in 1979 released new guidelines for snakebite first aid,<ref>{{Cite web|url=http://nla.gov.au/nla.news-article250876011|title=SAFER FIRST AID, Papua New Guinea Post-Courier|date=18 April 1979|pages=11|via=Trove}}</ref> and a new test for snakebites that would identify which snake had envenomated the victim.<ref>{{Cite web|url=http://nla.gov.au/nla.news-article110609725|title=New test for snake bites, The Canberra Times|date=30 October 1979|pages=14|via=Trove}}</ref>

Other major achievements of CSL include:<ref>{{Cite news|title=Blood, sweat and tears of the CSL century|last=Tasker|first=Sarah-Jane|date=23 April 2016|publisher=The Australian}}</ref>
* early production of [[Insulin (medication)|insulin]] for treatment of Australian diabetics (1923)
* development of a [[tetanus]] vaccine (1938)
* development of a combined vaccine for [[diphtheria]], tetanus and [[whooping cough]] (1953)
* rapid adoption and production of a [[polio vaccine]] (1956)
* development of a multi-purpose animal vaccine covering pulpy kidney ([[enterotoxemia]]), tetanus, [[black disease]], [[Malignant edema|malignant oedema]] and [[Blackleg (disease)|blackleg]] (1961)
* production of Rhesus (D) immunoglobulin to prevent haemolytic disease in newborns due to [[Rh disease|Rh factor incompatibility]] (1966–67)
* pioneering heat treatment to protect blood and plasma products from infection with [[HIV]] (1983)
* collaboration on development of the world's first [[human papillomavirus]] vaccine, [[Gardasil]], building on the pioneering work by [[Ian Frazer|Professor Ian Frazer]] (1994–2005).<ref>{{cite web|url=https://www.uniquest.com.au/filething/get/8631/Gardasil%20Commercialisation%20Story.pdf|title=A global solution to reducing cervical cancer|website=Uniquest commercialisation stories|publisher=The University of Queensland|access-date=29 April 2016}}</ref>